Table 2.
Minimum inhibitory concentration (MIC) values of the new hybrid compounds against the indicated Gram-negative bacterial strains.
| Cpd. | MIC [µg/mL] 1 | ||||
|---|---|---|---|---|---|
| A. baumannii ATCC 17978 | P. aeruginosa ATCC 27863 | K. pneumoniae ATCC 10031 | E. cloacae spp. cloacae ATCC 13047 | E. coli ATCC 25922 | |
| 3a | 16 | 64 | 0.5 | 4 | 2 |
| (23.4 µM) | (93.6 µM) | (0.73 µM) | (5.85 µM) | (2.93 µM) | |
| 3b | >64 | >64 | >64 | >64 | >64 |
| (>81.0 µM) | (>81.0 µM) | (>81.0 µM) | (>81.0 µM) | (>81.0 µM) | |
| 7a | >64 | >64 | 4 | >64 | >64 |
| (>86.4 µM) | (>86.4 µM) | (5.40 µM) | (>86.4 µM) | (>86.4 µM) | |
| 7b | >64 | >64 | 8 | >64 | >64 |
| (>84.8 µM) | (>84.8 µM) | (10.6 µM) | (>84.8 µM) | (>84.8 µM) | |
| 11a | >64 | >64 | 4 | 64 | 32 |
| (>82.9 µM) | (>82.9 µM) | (5.18 µM) | (82.9 µM) | (41.5 µM) | |
| 11b | 64 | >64 | 1 | 16 | 4 |
| (72.9 µM) | (>72.9 µM) | (1.14 µM) | (18.2 µM) | (4.56 µM) | |
| 1a 2 | 4 | 8 | 1 | >64 | 4 |
| (10.8 µM) | (21.6 µM) | (2.70 µM) | (>173 µM) | (10.8 µM) | |
| 1b 3 | 2 | 2 | 4 | >64 | 16 |
| (4.20 µM) | (4.20 µM) | (8.40 µM) | (>134 µM) | (33.6 µM) | |
| CP 4 | 0.25 | 0.25 | <0.03125 | <0.03125 | <0.03125 |
| (0.75 µM) | (0.75 µM) | (<0.0943 µM) | (<0.0943 µM) | (<0.0943 µM) | |
1 MIC, minimum inhibitory concentration; 2, 3 1a and 1b, GyrB and ParE inhibitors; 4 CP, ciprofloxacin. Measurements were performed according to the Clinical and Laboratory Standards Institute guidelines, with three independent measurements.